---
author: mike
pubDatetime: 2024-04-26 19:03:01.643683
modDatetime: 2024-04-26 19:03:01.643683
title: Q124 GILD earnings
slug: q124-gild-earnings
featured: false
ogImage: /assets/images/250_250.png
tags:
- transcripts
- earnings
- biotech
description: Earnings summary for Q124 Gilead Sciences
---
### Earnings Results
- Total product sales, excluding Veklury, grew by 6% year-over-year to $6.1 billion, driven by higher demand across HIV, oncology, and liver disease segments.
- Veklury sales totaled $555 million, tracking with rates of hospitalization for COVID-19.
- HIV product sales increased by 4% year-over-year.
- Oncology product sales were up 18%, driven by Trodelvy and transformative cell therapies.
- Liver disease sales saw a 9% year-over-year increase to $737 million.
- GAAP diluted earnings per share were negatively impacted by $1.32, mainly due to a $3.9 billion charge associated with the Sema Bay acquisition.
- Non-GAAP diluted EPS, excluding the IP R&D charge, would have been $1.82 for the first quarter.

### Future Guidance
- Gilead maintains total product sales forecast for 2024 in the range of $27.1 billion to $27.5 billion.
- Excluding Veklury, total product sales are expected to be between $25.8 billion and $26.2 billion, indicating a 4% to 6% growth for the base business year-over-year.
- Veklury sales are anticipated to be approximately $1.3 billion for the full year.
- Product gross margin is projected to be in the 85% to 86% range.
- Research and Development (R&D) expenses are expected to grow at the higher end of the low to mid-single-digit percentage range, with SG&A expenses predicted to decline by a mid-single-digit percentage relative to 2023.
- Acquired IP R&D is forecasted to be about $4.4 billion, with operating income projected to be in the range of $7 billion to $7.5 billion.
- The effective tax rate for 2024 is expected to be approximately 30%, reflecting the nondeductible impact of the CymaBay acquisition, translating into diluted EPS in the range of $3.45 to $3.85.

### Trends, Market Conditions, Sentiment
- The consistent growth in HIV, oncology, and liver disease segments highlights the robust demand and solid commercial performance of Gilead's portfolio.
- There's a strong focus on cell therapy expansion, with plans to into community networks in the U.S., double manufacturing capacity, and move into new indications with next-generation products.
- The close of the Sema Bay acquisition and the filing for regulatory approval of seladelpar indicates Gilead's strategic focus on addressing significant unmet needs in liver disease.
- The decline in Veklury sales reflects the changing dynamics of COVID-19 hospitalization rates, indicating a potential shift in the market dependency on COVID-19 related revenues.
- Gilead is demonstrating a focused execution on both near-term execution and longer-term plans, with 54 clinical programs in play and no major patent expiration for the decade, highlighting optimism for sustained growth and innovation.

### Notable Quotes
- "We have a lot of tension and a lot to deliver." - Gilead teams acknowledged for their contribution towards a strong first quarter.
- "This is a time of focused execution for Gilead." - Stressed the importance of disciplined approach in achieving upcoming milestones.
- "...expand our therapies to new populations positively impacting more people all over the world." - Commitment towards expanding the reach of current and future therapies to benefit more patients globally.